Generic sales push net of Glenmark fivefold

has reported a fivefold jump in its consolidated net profit at Rs 213 crore for the quarter ended December 31, against Rs 45 crore, on account of growth across all business verticals.

Consolidated net sales rose to Rs 1,381 crore for the quarter against Rs 1,031 crore for the corresponding period last year.

Specialty formulation business recorded a growth of 34 per cent at Rs 735 crore. Revenue from the generics business grew by 33 per cent at Rs 581 crore. US generics business grew by 37 per cent, while India formulations business grew by 30 per cent.

Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals, “We continue to maintain our high growth trajectory by recording a strong sales growth of over 30 per cent for the third quarter. The US, India and Russia markets performed exceptionally well and continue to drive growth for the company.”

Net profit for nine months ended December 31, 2012 stood at Rs 448 crore as compared to Rs 310 crore.

image
Business Standard
177 22
Business Standard

Generic sales push net of Glenmark fivefold

BS Reporter  |  Mumbai 



has reported a fivefold jump in its consolidated net profit at Rs 213 crore for the quarter ended December 31, against Rs 45 crore, on account of growth across all business verticals.

Consolidated net sales rose to Rs 1,381 crore for the quarter against Rs 1,031 crore for the corresponding period last year.

Specialty formulation business recorded a growth of 34 per cent at Rs 735 crore. Revenue from the generics business grew by 33 per cent at Rs 581 crore. US generics business grew by 37 per cent, while India formulations business grew by 30 per cent.

Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals, “We continue to maintain our high growth trajectory by recording a strong sales growth of over 30 per cent for the third quarter. The US, India and Russia markets performed exceptionally well and continue to drive growth for the company.”

Net profit for nine months ended December 31, 2012 stood at Rs 448 crore as compared to Rs 310 crore.

RECOMMENDED FOR YOU

Generic sales push net of Glenmark fivefold

Glenmark Pharmaceuticals has reported a fivefold jump in its consolidated net profit at Rs 213 crore for the quarter ended December 31, against Rs 45 crore, on account of growth across all business verticals.

has reported a fivefold jump in its consolidated net profit at Rs 213 crore for the quarter ended December 31, against Rs 45 crore, on account of growth across all business verticals.

Consolidated net sales rose to Rs 1,381 crore for the quarter against Rs 1,031 crore for the corresponding period last year.

Specialty formulation business recorded a growth of 34 per cent at Rs 735 crore. Revenue from the generics business grew by 33 per cent at Rs 581 crore. US generics business grew by 37 per cent, while India formulations business grew by 30 per cent.

Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals, “We continue to maintain our high growth trajectory by recording a strong sales growth of over 30 per cent for the third quarter. The US, India and Russia markets performed exceptionally well and continue to drive growth for the company.”

Net profit for nine months ended December 31, 2012 stood at Rs 448 crore as compared to Rs 310 crore.

image
Business Standard
177 22
Widgets Magazine

More News

Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard